HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib
文献类型：期刊论文
| 作者 | Fan, Ying1,2,3,4; Qin, Jing1,3,4; Han, Na1,3,4; Lu, Hongyang1,2,3,4 |
| 刊名 | ANNALS OF PALLIATIVE MEDICINE
 |
| 出版日期 | 2022-04-01 |
| 卷号 | 11 |
| 关键词 | Leptomeningeal metastasis (LM) cerebrospinal fluid HER2 exon 20 insertion mutations poziotinib case report |
| ISSN号 | 2224-5820 |
| DOI | 10.21037/apm-21-213 |
| 通讯作者 | Lu, Hongyang(luhy@zjcc.org.cn) |
| 英文摘要 | Leptomeningeal metastasis (LM) is associated with poor prognosis and represents a terminal event of non-small cell lung cancers (NSCLC). In previous studies, most of LM-patients have detected epidermal growth factor receptor (EGFR) mutation and responded to the third generation of EGFR-tyrosine kinase inhibitor (TKI). This study aimed to report a case of ERBB2 (HER2) exon 20 insertion mutations in the cerebrospinal fluid (CSF) of LM-patient which response to poziotinib. At the beginning, postoperative pathology showed a primary invasive adenocarcinoma with no mutations in EGFR and ROS-1. Pemetrexed plus carboplatin combined with bevacizumab was administered as the first-line followed by bevacizumab alone for continuation maintenance therapy. Targeted therapy and immunotherapy were given after the disease progressed in two months. Subsequently, the patient developed mental symptoms and adenocarcinoma cells were found in the CSF. Next-generation sequencing (NGS) results showed HER2 exon 20 insertion mutations in the primary tissue, CSF and plasma samples. Then, poziotinib was administered and the symptoms improved significantly after 3 days and the progress free survival was nearly 2 months. Therefore, we speculate that the CSF concentration and penetration rate of poziotinib may significantly higher than of other TKIs so that it achieves a higher CSF concentration than standard dosing, and successfully controlled LM. It may provide a new therapeutic option for LM-patient and may be especially who are lung adenocarcinoma with HER2 exon 20 insertion. |
| WOS关键词 | CANCER PATIENTS ; NSCLC PATIENTS ; EGFR ; CARCINOMATOSIS ; ERLOTINIB ; BLOCKADE ; SURVIVAL |
| 资助项目 | Zhejiang Province Medical Science and Technology Project[2019ZH019] ; CSCO-Haosen Cancer Research Foundation[Y-HS2017-044] |
| WOS研究方向 | Health Care Sciences & Services |
| 语种 | 英语 |
| WOS记录号 | WOS:000798306200020 |
| 出版者 | AME PUBL CO |
| 资助机构 | Zhejiang Province Medical Science and Technology Project ; CSCO-Haosen Cancer Research Foundation |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/131071]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Lu, Hongyang |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Zhejiang Key Lab Diag & Treatment Technol Thorac, Hangzhou 310022, Peoples R China 2.Wenzhou Med Univ, Clin Med Coll 1, Wenzhou 310022, Peoples R China 3.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou 310022, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Med Oncol, Canc Hosp, Hangzhou 310022, Peoples R China |
| 推荐引用方式 GB/T 7714 | Fan, Ying,Qin, Jing,Han, Na,et al. HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib[J]. ANNALS OF PALLIATIVE MEDICINE,2022,11. |
| APA | Fan, Ying,Qin, Jing,Han, Na,&Lu, Hongyang.(2022).HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib.ANNALS OF PALLIATIVE MEDICINE,11. |
| MLA | Fan, Ying,et al."HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib".ANNALS OF PALLIATIVE MEDICINE 11(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。